IBDEI0NC ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11430,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11430,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,11430,1,5,0)
 ;;=5^Hx of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,11430,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,11431,0)
 ;;=V10.46^^64^697^48
 ;;^UTILITY(U,$J,358.3,11431,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11431,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,11431,1,5,0)
 ;;=5^Hx of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,11431,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,11432,0)
 ;;=V11.0^^64^697^50
 ;;^UTILITY(U,$J,358.3,11432,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11432,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,11432,1,5,0)
 ;;=5^Hx of Schizophrenia
 ;;^UTILITY(U,$J,358.3,11432,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,11433,0)
 ;;=V10.83^^64^697^51
 ;;^UTILITY(U,$J,358.3,11433,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11433,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,11433,1,5,0)
 ;;=5^Hx of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,11433,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,11434,0)
 ;;=V15.1^^64^697^53
 ;;^UTILITY(U,$J,358.3,11434,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11434,1,4,0)
 ;;=4^V15.1
 ;;^UTILITY(U,$J,358.3,11434,1,5,0)
 ;;=5^Hx of Surgery To Heart And Great Vessels
 ;;^UTILITY(U,$J,358.3,11434,2)
 ;;=^295283
 ;;^UTILITY(U,$J,358.3,11435,0)
 ;;=V15.82^^64^697^57
 ;;^UTILITY(U,$J,358.3,11435,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11435,1,4,0)
 ;;=4^V15.82
 ;;^UTILITY(U,$J,358.3,11435,1,5,0)
 ;;=5^Hx of Tobacco Use (not current)
 ;;^UTILITY(U,$J,358.3,11435,2)
 ;;=Hx of Tobacco Use (not current)^303405
 ;;^UTILITY(U,$J,358.3,11436,0)
 ;;=V12.01^^64^697^54
 ;;^UTILITY(U,$J,358.3,11436,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11436,1,4,0)
 ;;=4^V12.01
 ;;^UTILITY(U,$J,358.3,11436,1,5,0)
 ;;=5^Hx of TB
 ;;^UTILITY(U,$J,358.3,11436,2)
 ;;=Hx of TB^303393
 ;;^UTILITY(U,$J,358.3,11437,0)
 ;;=V13.01^^64^697^36
 ;;^UTILITY(U,$J,358.3,11437,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11437,1,4,0)
 ;;=4^V13.01
 ;;^UTILITY(U,$J,358.3,11437,1,5,0)
 ;;=5^Hx of Kidney Stones
 ;;^UTILITY(U,$J,358.3,11437,2)
 ;;=Hx of Kidney Stones^303403
 ;;^UTILITY(U,$J,358.3,11438,0)
 ;;=V12.51^^64^697^59
 ;;^UTILITY(U,$J,358.3,11438,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11438,1,4,0)
 ;;=4^V12.51
 ;;^UTILITY(U,$J,358.3,11438,1,5,0)
 ;;=5^Hx of Venous Thrombosis And Embolism
 ;;^UTILITY(U,$J,358.3,11438,2)
 ;;=^303397
 ;;^UTILITY(U,$J,358.3,11439,0)
 ;;=V17.89^^64^697^18
 ;;^UTILITY(U,$J,358.3,11439,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11439,1,4,0)
 ;;=4^V17.89
 ;;^UTILITY(U,$J,358.3,11439,1,5,0)
 ;;=5^Family h/o Musculosk Disease
 ;;^UTILITY(U,$J,358.3,11439,2)
 ;;=^332861
 ;;^UTILITY(U,$J,358.3,11440,0)
 ;;=V12.54^^64^697^56
 ;;^UTILITY(U,$J,358.3,11440,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11440,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,11440,1,5,0)
 ;;=5^Hx of TIA
 ;;^UTILITY(U,$J,358.3,11440,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,11441,0)
 ;;=V12.54^^64^697^52
 ;;^UTILITY(U,$J,358.3,11441,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11441,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,11441,1,5,0)
 ;;=5^Hx of Stroke w/o Residual
 ;;^UTILITY(U,$J,358.3,11441,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,11442,0)
 ;;=V15.88^^64^697^33
 ;;^UTILITY(U,$J,358.3,11442,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11442,1,4,0)
 ;;=4^V15.88
 ;;^UTILITY(U,$J,358.3,11442,1,5,0)
 ;;=5^Hx of Fall(s)
 ;;^UTILITY(U,$J,358.3,11442,2)
 ;;=^332859
 ;;^UTILITY(U,$J,358.3,11443,0)
 ;;=V13.59^^64^697^42
 ;;^UTILITY(U,$J,358.3,11443,1,0)
 ;;=^358.31IA^5^2
